222 related articles for article (PubMed ID: 19299733)
1. Immunologic and therapeutic synergy of IL-27 and IL-2: enhancement of T cell sensitization, tumor-specific CTL reactivity and complete regression of disseminated neuroblastoma metastases in the liver and bone marrow.
Salcedo R; Hixon JA; Stauffer JK; Jalah R; Brooks AD; Khan T; Dai RM; Scheetz L; Lincoln E; Back TC; Powell D; Hurwitz AA; Sayers TJ; Kastelein R; Pavlakis GN; Felber BK; Trinchieri G; Wigginton JM
J Immunol; 2009 Apr; 182(7):4328-38. PubMed ID: 19299733
[TBL] [Abstract][Full Text] [Related]
2. IL-27 mediates complete regression of orthotopic primary and metastatic murine neuroblastoma tumors: role for CD8+ T cells.
Salcedo R; Stauffer JK; Lincoln E; Back TC; Hixon JA; Hahn C; Shafer-Weaver K; Malyguine A; Kastelein R; Wigginton JM
J Immunol; 2004 Dec; 173(12):7170-82. PubMed ID: 15585838
[TBL] [Abstract][Full Text] [Related]
3. Increasing infiltration and activation of CD8+ tumor-infiltrating lymphocytes after eliminating immune suppressive granulocyte/macrophage progenitor cells with low doses of interferon gamma plus tumor necrosis factor alpha.
Young MR; McCloskey G; Wright MA; Pak AS
Cancer Immunol Immunother; 1994 Jan; 38(1):9-15. PubMed ID: 8299123
[TBL] [Abstract][Full Text] [Related]
4. Combined interleukin 1/interleukin 2 therapy of mice injected with highly metastatic Friend leukemia cells: host antitumor mechanisms and marked effects on established metastases.
Ciolli V; Gabriele L; Sestili P; Varano F; Proietti E; Gresser I; Testa U; Montesoro E; Bulgarini D; Mariani G
J Exp Med; 1991 Feb; 173(2):313-22. PubMed ID: 1671080
[TBL] [Abstract][Full Text] [Related]
5. Synergistic interleukin-18 and low-dose interleukin-2 promote regression of established murine neuroblastoma in vivo.
Redlinger RE; Mailliard RB; Lotze MT; Barksdale EM
J Pediatr Surg; 2003 Mar; 38(3):301-7; discussion 301-7. PubMed ID: 12632339
[TBL] [Abstract][Full Text] [Related]
6. Adoptive transfer of cytotoxic T lymphocytes induced by CD86-transfected tumor cells suppresses multi-organ metastases of C1300 neuroblastoma in mice.
Enomoto A; Kato K; Yagita H; Okumura K
Cancer Immunol Immunother; 1997 Jun; 44(4):204-10. PubMed ID: 9222278
[TBL] [Abstract][Full Text] [Related]
7. OX40 ligation enhances primary and memory cytotoxic T lymphocyte responses in an immunotherapy for hepatic colon metastases.
Pan PY; Zang Y; Weber K; Meseck ML; Chen SH
Mol Ther; 2002 Oct; 6(4):528-36. PubMed ID: 12377195
[TBL] [Abstract][Full Text] [Related]
8. Intratumoral delivery of encapsulated IL-12, IL-18 and TNF-alpha in a model of metastatic breast cancer.
Sabel MS; Su G; Griffith KA; Chang AE
Breast Cancer Res Treat; 2010 Jul; 122(2):325-36. PubMed ID: 19802695
[TBL] [Abstract][Full Text] [Related]
9. Targeted interleukin-2 therapy for spontaneous neuroblastoma metastases to bone marrow.
Lode HN; Xiang R; Varki NM; Dolman CS; Gillies SD; Reisfeld RA
J Natl Cancer Inst; 1997 Nov; 89(21):1586-94. PubMed ID: 9362156
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic modulation of Akt activity and antitumor efficacy of interleukin-12 against orthotopic murine neuroblastoma.
Khan T; Hixon JA; Stauffer JK; Lincoln E; Back TC; Brenner J; Lockett S; Nagashima K; Powell D; Wigginton JM
J Natl Cancer Inst; 2006 Feb; 98(3):190-202. PubMed ID: 16449679
[TBL] [Abstract][Full Text] [Related]
11. Cellular mechanisms of interleukin-12-mediated neuroblastoma regression.
Redlinger RE; Shimizu T; Remy T; Alber S; Watkins SC; Barksdale EM
J Pediatr Surg; 2003 Feb; 38(2):199-204. PubMed ID: 12596103
[TBL] [Abstract][Full Text] [Related]
12. Gene therapy with a single chain interleukin 12 fusion protein induces T cell-dependent protective immunity in a syngeneic model of murine neuroblastoma.
Lode HN; Dreier T; Xiang R; Varki NM; Kang AS; Reisfeld RA
Proc Natl Acad Sci U S A; 1998 Mar; 95(5):2475-80. PubMed ID: 9482910
[TBL] [Abstract][Full Text] [Related]
13. Transient depletion of CD4(+) T cells augments IL-21-based immunotherapy of disseminated neuroblastoma in syngeneic mice.
Croce M; Corrias MV; Orengo AM; Brizzolara A; Carlini B; Borghi M; Rigo V; Pistoia V; Ferrini S
Int J Cancer; 2010 Sep; 127(5):1141-50. PubMed ID: 20039320
[TBL] [Abstract][Full Text] [Related]
14. Induction of protective immune responses against NXS2 neuroblastoma challenge in mice by immunotherapy with GD2 mimotope vaccine and IL-15 and IL-21 gene delivery.
Kowalczyk A; Wierzbicki A; Gil M; Bambach B; Kaneko Y; Rokita H; Repasky E; Fenstermaker R; Brecher M; Ciesielski M; Kozbor D
Cancer Immunol Immunother; 2007 Sep; 56(9):1443-58. PubMed ID: 17597331
[TBL] [Abstract][Full Text] [Related]
15. Enhanced antitumor effects of bone marrow transplantation in combination with fibroblast-mediated IL-2 and IL-3 gene therapy.
Cao X; Li Q; Ju DW; Wang Q; Tao Q; Wang J
Transplantation; 1999 May; 67(9):1242-50. PubMed ID: 10342316
[TBL] [Abstract][Full Text] [Related]
16. Combination of interleukin 12 and interferon alpha gene therapy induces a synergistic antitumor response against colon and renal cell carcinoma.
Mendiratta SK; Quezada A; Matar M; Thull NM; Bishop JS; Nordstrom JL; Pericle F
Hum Gene Ther; 2000 Sep; 11(13):1851-62. PubMed ID: 10986558
[TBL] [Abstract][Full Text] [Related]
17. Combined therapy of local and metastatic 4T1 breast tumor in mice using SU6668, an inhibitor of angiogenic receptor tyrosine kinases, and the immunostimulator B7.2-IgG fusion protein.
Huang X; Wong MK; Yi H; Watkins S; Laird AD; Wolf SF; Gorelik E
Cancer Res; 2002 Oct; 62(20):5727-35. PubMed ID: 12384531
[TBL] [Abstract][Full Text] [Related]
18. Curative effects of combination therapy with lentinan and interleukin-2 against established murine tumors, and the role of CD8-positive T cells.
Suzuki M; Kikuchi T; Takatsuki F; Hamuro J
Cancer Immunol Immunother; 1994 Jan; 38(1):1-8. PubMed ID: 8299113
[TBL] [Abstract][Full Text] [Related]
19. Interleukin-7 mediates the generation and expansion of murine allosensitized and antitumor CTL.
Jicha DL; Schwarz S; Mulé JJ; Rosenberg SA
Cell Immunol; 1992 Apr; 141(1):71-83. PubMed ID: 1555257
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of TC-1 cytokine production, effector cytotoxic T lymphocyte development and alloantibody production by 2,3,7,8-tetrachlorodibenzo-p-dioxin.
Kerkvliet NI; Baecher-Steppan L; Shepherd DM; Oughton JA; Vorderstrasse BA; DeKrey GK
J Immunol; 1996 Sep; 157(6):2310-9. PubMed ID: 8805628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
